Media headlines about Neuralstem (NASDAQ:CUR) have trended somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Neuralstem earned a news impact score of 0.24 on Accern’s scale. Accern also gave news stories about the company an impact score of 47.9489175371079 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:

Separately, ValuEngine lowered Neuralstem from a “hold” rating to a “sell” rating in a report on Tuesday, July 25th.

Shares of Neuralstem (NASDAQ CUR) traded up 4.35% during mid-day trading on Friday, hitting $1.20. The stock had a trading volume of 488,496 shares. The stock’s market capitalization is $14.54 million. The stock has a 50 day moving average of $2.77 and a 200-day moving average of $4.26. Neuralstem has a 52 week low of $0.22 and a 52 week high of $6.60.

Neuralstem (NASDAQ:CUR) last issued its earnings results on Tuesday, August 8th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($9.49) by $9.10. Neuralstem had a negative net margin of 198,573.91% and a negative return on equity of 321.78%. On average, equities research analysts predict that Neuralstem will post ($2.26) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece was reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at

Neuralstem Company Profile

Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.

Insider Buying and Selling by Quarter for Neuralstem (NASDAQ:CUR)

Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with's FREE daily email newsletter.